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Abstract 
Background: Chronic breathlessness is a neglected symptom of advanced diseases.  
Aim: To examine the effect of airflow for chronic breathlessness relief.  
Design: Exploratory systematic review and meta-analysis.  
Data sources: Medline, CINAHL, AMED and Cochrane databases were searched (1985 – 
2018) for observational studies or randomised controlled trials of airflow as intervention or 
comparator. Selection against pre-defined inclusion criteria, quality-appraisal and data 
extraction were conducted by two independent reviewers with access to a third for unresolved 
differences. “Before and after” breathlessness measures from airflow arms were analysed. 
Meta-analysis was carried out where possible. 
Results: 16/78 studies (n=929) were included; 11 randomised controlled trials of oxygen vs 
medical air, four randomised controlled trials and one fan cohort study. Three meta-analyses 
were possible: i) Fan at rest in three studies (n=111) offered significant benefit for 
breathlessness intensity (0-100mm Visual Analogue Scale and 0- 10 Numerical Rating 
Scale), mean difference -11.17 (95% confidence intervals -16.60 to -5.74), p=0.06 I² 64%.  ii) 
Medical air via nasal cannulae at rest in two studies (n=89) improved breathlessness intensity 
(visual analogue scale), mean difference -12.0mm, 95% confidence intervals -7.4 to -16.6, 
P<0.0001 I² =0%. iii) Medical airflow during a constant load exercise test before and after 
rehabilitation (n=29) in two studies improved breathlessness intensity (mBorg, 0-10) mean 
difference -2.9, 95% confidence intervals -3.2 to -2.7, p<0.0001 I² =0%.  
Conclusion: Airflow appears to offer meaningful relief of chronic breathlessness and should 
be considered as an adjunct treatment in the management of breathlessness.  
 
Keywords:   
• dyspnea,  
• self-management,  
• review,  
• airflow (relevant term as the intervention subject heading) 
  
What is already known? 
 
• Randomised controlled trials and cohort data have demonstrated that airflow delivered 
from the fan at rest offers significant relief of breathlessness.    
• Systematic review and randomised controlled trials of oxygen vs medical air have 
failed to demonstrate additional benefit from oxygen therapy and suggest that medical 
air delivery, airflow, is likely to be an active intervention. 
• All current evidence available for the effect of airflow for chronic breathlessness 
relief has not been explored using systematic review methods.  
 
What this paper adds 
 
This exploratory systematic review and meta-analyses provide promising data to suggest that: 
• airflow from the fan at rest improves breathlessness in people with breathlessness due 
to a variety of causes  
• airflow delivered as cylinder medical air at rest improves breathlessness in advanced 
cancer  
• airflow delivered as cylinder medical air during a constant load exercise test in people 
with chronic obstructive pulmonary disease and who have completed pulmonary 
rehabilitation 
 
Implications for practice and theory  
• Clinicians should consider the fan as an adjunct to treatment for breathlessness at rest 
in patients who do not require oxygen-enriched air. 
• Airflow may benefit exertion-induced breathlessness, but further work is required to 
investigate the role of the fan with everyday general activity and in relation to 
exercise. 
• Recovery time from exertion-induced breathlessness, self-efficacy and daily activity 
are key outcomes to explore in future studies of airflow. 
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Introduction 
Breathlessness is a common, often poorly managed symptom in people with advanced 
diseases. It is associated with reduced quality of life (1), decreased activities of daily living 
(2), unplanned emergency hospital attendance and admission. (3-5) Breathlessness inflicts 
devastating and disabling physical, psychological and social burden on normal daily life for 
the patient, carers and close family members (6-8). Chronic breathlessness, that is, 
breathlessness that persists despite optimal treatment for the underlying pathophysiology and 
causing such disability (9), all too often is left for patients to manage themselves despite a 
developing evidence base for interventions targeted at the breathlessness itself. 
Growing evidence supports complex non-pharmacological interventions to reduce the impact 
of the symptom and improve quality of life. (10-12) Components target peripheral and central 
afferent sources of breathlessness sensation, such as facial airflow delivered by the battery-
operated hand-held fan (fan). (13-17) Cooling of the facial skin innervated by the 2nd and 3rd 
branches of the trigeminal nerve, nasal mucosae or the upper airway flow receptors could 
modulate the central perception of breathlessness leading to decreased neural respiratory 
drive, thereby reducing the sensation of breathlessness. (18-22) A recent multi-methods 
secondary analysis of qualitative interview data from three studies found that 80/111 (72%) 
participants experienced benefit when the fan was used in conjunction with other components 
of a complex intervention. (23) Airflow delivered from the fan may offer a valuable 
contribution to the self-management of chronic breathlessness (13, 15, 23), and has been 
identified as a potentially useful strategy in a variety of situations,  e.g. breathlessness crisis 
(24), a component of pulmonary rehabilitation to assist recovery from exercise, or with 
general everyday activities. (15) 
Systematic reviews of oxygen in a variety of non-hypoxic patient groups (cancer, chronic 
heart failure, kyphoscoliosis, chronic obstructive pulmonary disease and interstitial lung 
disease) have not demonstrated additional benefit from oxygen therapy over medical air 
delivery. (25-30) An updated Cochrane review of chronic obstructive pulmonary disease 
found low quality evidence for modest relief of breathlessness. (31) The results from a large, 
adequately powered trial that randomised 239 participants (chronic obstructive pulmonary 
disease 63%, cancer 16%) to receive at least 15 hours a day of oxygen or medical air 
delivered via home concentrator for seven days reaffirms earlier suggestion that medical air 
5 
 
used in the placebo arm may not be an inert comparator as previously thought and points to 
the likelihood of an active intervention. (29, 32) Therefore the placebo arm of oxygen studies 
may provide useful preliminary data regarding the role of airflow for the relief of chronic 
breathlessness. This systematic review aims to identify and evaluate data from studies of 
airflow, both from studies of the hand-held fan and the comparator arm data for 
breathlessness intensity from oxygen studies, analysed as “before and after” airflow exposure 
cohort data.  
Aim 
To examine the current evidence for the effectiveness of airflow for the relief of chronic 
breathlessness.  
Methods 
The systematic review methods employed an exploratory approach in that only the airflow 
arm of studies were used and the data analysed as cohort “before and after” treatment.  
Study design 
The search methods employed are adapted from the Cochrane Handbook of Systematic 
Reviews (33) and reported in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses. (34) A review protocol is not pre-registered but available from 
the University of Hull Library (Flavia Swan PhD Thesis). 
Inclusion and exclusion criteria  
Types of studies 
Randomised controlled trials, controlled clinical trials (quasi-randomised experimental trials 
with or without blinding) and observational cohort studies were included. 
6 
 
Types of participants 
Adults with chronic breathlessness from any advanced disease aetiology as shown below: 
• Malignancy: advanced primary and metastatic cancer patients, who have undergone 
disease treatments like chemotherapy, radiotherapy or surgical interventions. 
• Chronic Obstructive Pulmonary Disease with forced expiratory volume in 1 second of 
less than 50% predicted value 
• Interstitial lung disease or pulmonary fibrosis where breathlessness is present 
• Chronic heart failure: New York Heart Association stage III-IV 
• Motor Neurone disease and other neurological disease where breathlessness is present 
or forced vital capacity less than 80% predicted value 
• Kyphoscoliosis: a moderate - severe sideways and forwards curvature of the spine 
Cobb Angle > 50° and forced expiratory volume of less than 50% predicted value. 
 
Studies were included if at least 50% of the study population were classified as advanced, 
palliative or in the later stages of disease as defined above. These criteria were adapted from 
the Cochrane review of non-pharmacological interventions for breathlessness. (35) 
Studies of participants with mild hypo or normoxaemia, who do not fore-fill the criteria for 
long term oxygen therapy (36) were included. Studies of hypoxic participants or patients with 
any condition not assessed as progressive, refractory to treatment and advanced such as 
asthma were excluded. 
Types of exposure 
Airflow: i) delivered from either a fan (hand-held or table) or non-oxygen enriched 
compressed air, or from a non-invasive ventilatory method (nasal cannula, mask or 
mouthpiece), but not nasal intermittent positive pressure ventilation and ii) directed at the 
cheek of the face, nasal mucosae or mouth.  
Administration: as i) a single dose during ambulation, or at rest taken as needed (pro re 
nata),(37) ii) placebo short-burst oxygen therapy intermittent use before exercise or after 
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exercise for recovery (36) or iii) continuously over 15hr a day as placebo long-term oxygen 
therapy studies or during the night as placebo nocturnal oxygen therapy.(38) 
Studies where airflow was directly administered to the trachea, or at sub-zero temperatures 
were excluded. 
Types of outcome measure 
Unidimensional breathlessness outcomes 
ATS domains of dyspnea measurement (20) including breathlessness severity or intensity 
rated on uni-dimensional scales  as shown below: 
• Modified Borg Score, a categorical scale with ratio properties  
• Visual Analogue Scale, 0 - 100mm anchored 0 = no shortness of breath and 
100mm = shortness of breath as bad as can be  
• Numerical Rating Scales, 0-10 numbered scale anchored 0 = Not breathless at all 
and 10 the worst imaginable breathlessness  
• Likert scales with verbal responses such as “a bit better”, “much better” or “no 
difference” or any other validated uni-dimensional scale for measuring 
breathlessness. 
 
Studies were only included if they reported the breathlessness outcome at baseline and post-
treatment measured as either primary or secondary outcomes. If severity or intensity was 
measured as part of a multi-dimensional or composite scale, e.g. the Chronic Respiratory 
Questionnaire, that unidimensional measure of breathlessness was not extracted and analysed 
separately. Breathlessness related function/quality of life measures were not used as primary 
breathlessness outcomes in the absence of unidimensional scales.  
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Other Outcomes 
Other outcomes as shown below measured as either primary or secondary outcomes. 
• Participant preference and satisfaction with the treatment 
• Participant withdrawal and drop-out from the studies 
• Adverse effects recorded 
 
Data sources and searches  
Medline, CINAHL, AMED and Cochrane databases were searched (1985 – 2015; updated 
January 2018) for observational or randomised controlled trials of airflow as intervention vs 
control or as comparator vs oxygen. Reference lists were scanned. A full search strategy can 
be seen in Online Supplementary Table 1. 
Study selection 
Titles, abstracts (and, where unclear, full papers) were screened against the eligibility criteria 
by two independent reviewers FS and AN, with recourse to MJ as a third reviewer in case of 
disagreement.  
Data extraction and synthesis 
Baseline and post-intervention measures of breathlessness intensity were extracted from the 
fan studies and from the comparator arm of oxygen studies. Data were analysed as “before 
and after” airflow exposure cohort observational data.  
Risk of bias 
FS and AN judged the reporting quality and internal validity for each of the included studies. 
The cohort study was evaluated according to the Cochrane guidelines for assessing bias in a 
non-randomised study. (39) As there is no tool that is applicable directly to the data extracted 
from the randomised controlled trials control arms, we assessed instead the quality of the 
parent randomised controlled trials as a proxy marker for quality data. The randomised 
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controlled trials were assessed with the Cochrane Risk of bias tool. (33) See online 
Supplementary Table 2.  
Statistical Analysis 
Results from the meta-analyses were reported for the primary outcome, breathlessness 
intensity or severity where heterogeneity allowed, or where not possible these were described 
narratively. Numerical rating scales and visual analogue scales were combined by equating 
one point on a numerical rating scales scale to 10mm on a visual analogue scales. (40, 41) 
Data calculations for mean difference and standard deviation used STATA Version 12.1, 
Stata Corp LLC 
Texas 77845-4512, USA. Breathlessness measurements were analysed as continuous 
outcomes. Data from the placebo arm of cross-over randomised controlled trials were treated 
as single arm before-after studies. For studies that recorded median values, the mean were 
calculated from the extracted study data. (42) The I² statistic was used to assess 
heterogeneity. (43) Where the result indicated significant heterogeneity a random effects 
model was chosen, otherwise a fixed effects model was applied. All analyses were 
undertaken on Review Manager 5.5. A sensitivity analysis was attempted for any study 
identified as including a sub-group not fitting the review criteria of mild hypo or 
normoxaemia to assess for any significant difference in the breathlessness outcome between 
the hypoxic and non-hypoxic participants. 
Results 
A total of 403 records were identified for screening. After removal of duplicates, 78 records 
were reviewed. 14 abstracts were rejected for not meeting inclusion criteria; the remaining 64 
full text articles were assessed for eligibility. Of these, 16 studies met the review inclusion 
criteria and the other 48 studies were excluded (see Figure 1; flow chart (34) and Online 
Supplementary Table 3, eAppendix). 
Overall studies represented 929 participants (age median 61.5, range 33 to 90 years; 47% 
men) 
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Figure 1 Flow-diagram of study selection and retrieval (34) 
Airflow was delivered by fan (13, 14, 16, 17, 44) or as medical air. (29, 32, 45-53) See Table 
1 for study characteristics 
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Description of fan studies 
 
Design: five studies (n=230) used the fan. Two feasibility randomised controlled trials; (n 
=49), (13) and (n=30), (44), a feasibility cohort study (n=31), (14), a feasibility longitudinal 
RCT (n=70), (16) and a phase III cross-over randomised controlled trial (n=50), (17).  
 
Patient characteristics: Four studies recruited a mixed population of people with 
breathlessness due to a variety of advanced conditions including chronic obstructive 
pulmonary disease (n=101), cancer (n=55), heart failure (n=23) and other causes (n=21), (13, 
14, 16, 17), and one study recruited advanced cancer only (n=30). (44)  
 
Intervention and comparator characteristics: three studies used the fan to face at rest (14, 
17, 44), two with comparator groups; fan to leg (17), or no fan use and carer support (44), and 
the other was a cohort design. (14) One study assessed acceptability of the fan when used 
with general activity over 6 months compared with an acupressure wristband (16), and the 
remaining study assessed the fan when used with exercise advice over 4 weeks. (13) 
 
Breathlessness Outcome: Three studies focused on the sensory-perceptual domain of 
dyspnea measurement and used breathlessness intensity as the primary outcome (17) or main 
outcome (14, 44). These studies selected the visual analogue scale (17), the numerical rating 
scale (44), or both visual analogue scale and numerical rating scale (14). The other two 
studies assessed symptom impact as well as the sensory-perceptual domain. These studies 
selected the numerical rating scale breathlessness intensity (13) and the Modified Borg Scale 
of breathlessness severity. (16)  
Other outcomes: All of the fan studies reported participant withdrawals (13, 14, 16, 17, 44). 
These ranged from 0 to 6 participants. (13, 14, 44) One study reported that there were no 
adverse events (13) and the other fan studies did not include any adverse event details. (14, 
16, 17, 44) Airflow preferences were described in four fan studies (13, 16, 17, 44) and not in 
one study. (14) In addition, one study quantified the experience of fan use at 2 months. (16) 
Description of medical air studies 
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Design: eleven randomised controlled trials (n=699) used oxygen, helium hyperoxia or both 
gases for the intervention compared with medical air. (29, 32, 45-53) Study size ranged from 
16 to 239 participants. (29, 48) Four were cross-over (32, 48, 49, 51) and seven used a 
parallel group design. (29, 45-47, 50, 52, 53) Nine studies were double blind (29, 45-52), and 
two were single blind. (32, 53)  
 
Patient characteristics: the eleven studies represent; chronic obstructive pulmonary disease 
n=537, cancer n=109, other lung diseases n=21, cardiac disease n=14 and other causes n=18. 
Inclusion criteria required moderate to severe chronic obstructive pulmonary disease (45-50, 
52, 53), advanced cancer (51), or were a mixed population with no specific stipulation of 
severity. (29, 32)   
Intervention Characteristics: the source of airflow was an oxygen cylinder (32, 45-50), a 
sham concentrator (29), and a Douglas bag. (52) Two studies did not state the airflow source. 
(51, 53) Medical air or compressed air was delivered through nasal cannulae (29, 32, 45, 47, 
49-51, 53), face-mask and nasal cannula (48), a non-rebreathing face-mask (46) and through 
a mouthpiece. (52) The flow rates varied widely in the studies; 2l/minute (29, 45), 3l/minute 
(47), 4l/minute (32, 49, 51), 5l/minute (53), 6l/minute (50) and 8l/minute via nasal cannula or 
15l/minute with face mask. (48) Two studies did not report flow rate details. (46, 52) The 
timing of airflow delivery was; 15 minutes at rest (32, 51), with daily activity over 3 (50), or 
6 months (45), 15 hours a day over one week (29), or in conjunction with exertion-induced 
breathlessness during pulmonary rehabilitation, (46, 52, 53) or a walking test. (47-49) The 
pulmonary rehabilitation programme parameters for airflow delivery were with treadmill 
exercise 3 times a week for 30 minutes over two months (53), a cycle ergometer used 3 times 
a week for 30 minutes over 6 weeks (46), or 3 times a week for 20 minutes over two months. 
(52) The 6minute walk test parameters for airflow delivery were; i) three same day 6minute 
walk test s with 45 minutes washout, using room air for the basal walk and compressed air for 
the subsequent walks (47), ii) five 6minute walk test performed over three visits, (timing not 
stated) using room air for the practice walk on visit one and cylinder air for the two 66minute 
walk test s with 60 minute washout on visits two and three (48), and iii) three same day 
6minute walk test s using cylinder air with 20 minutes washout between tests at baseline, 6 
and 12 weeks as well as short burst use at home with daily activity during the study period. 
(49) 
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Breathlessness outcome: two studies focused on the sensory-perceptual domain of dyspnea 
measurement and recorded breathlessness intensity as a primary outcome with the visual 
analogue scale and Borg scale (32) or the visual analogue scale only. (51) All of the other 
studies focused on symptom impact as well as the sensory-perceptual domain. (29, 45-50, 52, 
53) Of these, three studies measured breathlessness intensity as a primary outcome with the 
numerical rating scale (29) or the Chronic Respiratory Questionnaire dyspnea domain. (45, 
50) The remaining six studies identified the modified Borg scale as one of the main outcomes 
(47-49, 52, 53) or a secondary measure. (46) One study in addition selected the Chronic 
Respiratory Questionnaire. (49) 
Other outcomes: participant withdrawals were reported in all of the studies (29, 32, 45-51, 
53), apart from one. (52) Five studies reported no withdrawals (32, 46-48, 51) and in the 
other five studies withdrawals ranged from 2 to 21 participants. (45, 53) adverse events were 
poorly reported with only two studies including details; “few” or “no adverse events”. (29, 
46) All of the other studies omitted reporting adverse events. (32, 45, 47-53) Airflow 
preferences were only reported in one study. (51) The remaining studies did not report 
airflow preferences (29, 32, 45-48, 50, 52, 53), although one study did quantify side-effects 
(29) and a second study examined preference for cylinder delivery of airflow. (50) 
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Table 1 Characteristics of included studies (fan) 
Study 
author 
Study Design Population 
(mean; standard 
deviation) 
Intervention Comparator Mode 
of gas 
delivery 
Dyspnea 
Outcome 
measure(s) 
Other Outcomes: 
withdrawals, Adverse 
Events (AE), airflow 
preferences 
Timing of 
measure
ment 
Results airflow arm only 
(before and after 
treatment) 
(mean; standard deviation) 
Improvement 
with airflow 
Yes/No 
Booth 
(2016) [14]  
Feasibility 
observational 
cohort 
n= 31 Males: 20 
Age mean: 74.8; 11.49  
Mixed population, non-
malignant, 
cardiorespiratory 
disease: 8 (26%) 
Baseline dyspnoea 
score: 
Mean Visual analogue 
scale 48mm; 27.4 
Hand-held 
fan to face 
No 
comparator 
group 
Airflow 
from 
hand-
held 
fan to 
face for 
5 
minutes  
Visual 
analogue 
scale 
(mm), 
numerical 
rating scale 
Withdrawals = 6 
AE and airflow 
preferences not 
reported 
After 5 
minutes 
at rest 
Visual analogue scale = 
Mean 35mm; 25.7 
after 5min air 
Mean change = 12mm; 
21.2 
Yes 
Bausewein  
(2010) [16] 
Feasibility 
longitudinal 
phase II 
randomised 
controlled trial 
n = 70 Males: 36  
Age mean: 65.6yrs SD 
8.80 chronic obstructive 
pulmonary disease = 45, 
cancer = 25 
Baseline dyspnoea 
score: 3.7; 1.83 
Hand-held 
fan to face 
Wristband Airflow 
from 
hand-
held 
fan 
Modified 
Borg score 
Withdrawals at 2 
months =16/33 (48%)  
AE not reported 
Airflow preferences: 
Positive = 13/38 
Negative = 7/38  
Monthly 
over 6 
months 
Mean Borg score change 
over 2 months = 0.6; 2.1, p 
= 0.90 
No, phase II 
not powered to 
test 
Galbraith 
(2010) [17] 
Cross-over 
randomised 
controlled trial 
n = 50 Males: 23 
Age mean: 71.3, range 
33-90yrs 
Mixed population; chronic 
obstructive pulmonary 
disease = 26, lung 
cancer = 11, heart 
disease = 15 
Baseline dyspnoea 
score:  
Hand-held 
fan to face 
Hand-held 
fan to leg 
Airflow 
from 
hand-
held 
fan to 
face for 
5 
minutes 
Visual 
analogue 
scale (mm) 
Withdrawals = 1 
AE not reported 
Airflow preferences: 
positive patient 
comments, numbers 
not reported 
After 5 
minutes 
at rest 
and after 
10 
minute 
washout 
Visual analogue scale = -
7.0mm Median change 
after 5 minutes Fan/face 
1st group (interquartile 
range 1.5 - 14.5) 
Visual analogue scale =  
-10.0mm Median change 
incl 10 minute washout 
Fan/face 1st group 
Yes 
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Visual analogue scale 
Fan/face 1st group = 
31mm; 12-61mm  
(interquartile range 3.5 – 
17), P=0.003  
Johnson  
(2016) [13] 
Feasibility 
phase II 
randomised 
controlled trial 
n =49 Males: 26 
Age mean: 68 (range 46-
88)  
Mixed population; chronic 
obstructive pulmonary 
disease = 28, cancer =9, 
heart disease = 5, others 
= 7 
Baseline dyspnoea score  
Mean numerical rating 
scale = 5.7; 1.5 
Hand-held 
fan to face at 
high or low 
flow rate 
Usual care: 
verbal and 
written 
exercise and 
breathlessne
ss 
management 
advice 
Airflow 
from 
hand-
held 
fan 
numerical 
rating scale 
Withdrawals = 6 
No Adverse events 
Airflow preference: 
positive patient 
comments, numbers 
not reported 
After 4 
weeks 
numerical rating scale = 
6.0; 2.0 at 4 weeks 
Mean change 0.0; 3.0 
No, phase II 
not powered to 
test 
Wong 
(2017) [44] 
Feasibility 
phase II 
randomised 
controlled trial 
n=30 Males: 14 
Age: not reported 
Lung cancer = 13, other 
cancers = 17 
Baseline dyspnoea score 
Control group: numerical 
rating scale mean 
5.6;1.55 
Intervention group: 
numerical rating scale 
mean 6.13; 2.48 
Table fan 
with low flow 
rate 
Placebo 
accompanie
d by carer  
Airflow 
from 
table 
fan to 
face for 
5 
minutes 
numerical 
rating scale 
No withdrawals 
Adverse events not 
reported 
Airflow preference: 
mixed patient 
comments, numbers 
not reported 
After 5 
minutes 
at rest 
numerical rating scale = 
4.60 after 5 minutes fan to 
face 
Mean change -1.53 (1.06) 
p< 0.001 
Yes 
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Table 1 Characteristics of included studies (medical air) 
Study author Study 
Design 
Population 
(mean; standard deviation) 
Intervention Comparator Mode of 
gas 
delivery 
Dyspnea 
Outcome 
measure(s) 
Other Outcomes: 
withdrawals, AE, 
airflow 
preferences 
Timing of 
measurement 
Results airflow 
arm only (before 
and after 
treatment) 
(mean; standard 
deviation) 
Improvement 
with airflow  
Yes/No 
Abernethy 
(2010) [29] 
Double-blind  
randomised 
controlled 
trial 
n = 239 Males: 63%   
Age mean: Air = 74yrs;10 
Mixed: chronic obstructive 
pulmonary disease = 152, 
Primary lung cancer = 33 
Baseline dyspnoea score: Am 
air = 4.6; 2.4  
Pm air = 4.7; 2.3 
Oxygen Room air via 
concentrator 
2l/min via 
nasal 
cannula for 
at least 
15hrs a 
day (long 
term 
oxygen 
therapy) 
numerical 
rating scale 
1-10 
Withdrawals = 15 
Few adverse 
events, number 
not reported 
Side-effects 
reported 
Airflow 
preferences not 
reported, oxygen 
only 
Am and pm 
each day, 
within 30 
minutes of 
waking and 
bedtime for 7 
days 
Am = -0.7  
numerical rating 
scale point 
change   
Pm = -0.5  
numerical rating 
scale point 
change, (p = 0.5) 
Yes 
Booth (1996) 
[32] 
Single-blind 
cross-over  
randomised 
controlled 
trial 
n = 38 Males: 22 
Age Median: 71 Range: 54-
90yrs  
Lung Cancer 20,  chronic 
obstructive pulmonary disease 
13, Cardiac 4 
Baseline dyspnoea score:  
Visual analogue scale 59mm 
Oxygen Cylinder air 4l/minute 
for 15 
minutes via 
nasal 
cannula  
Visual 
analogue 
scale (mm) 
Modified 
Borg Scale 
No withdrawals 
Adverse events 
and airflow 
preferences not 
reported 
 
After 15 
minutes of 
breathing 
oxygen or air 
at rest. 
Visual analogue 
scale = -11mm 
change after air  
48mm, p<0.001 
Yes 
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Eaton (2006) 
[45] 
Double-blind 
parallel  
randomised 
controlled 
trial 
n = 78 Males: 36  
Age mean: 77.3yrs; 7.06 
Moderate/severe  chronic 
obstructive pulmonary disease 
Baseline chronic respiratory 
questionnaire score: Air = 
17.5; 4.2 
Oxygen Cylinder air 2l/minute 
via nasal 
cannula 
over 6 
months 
(SBOT) 
CRQ Withdrawals = 21 
Adverse events  
and airflow 
preferences not 
reported 
Monthly over 6 
months 
chronic respiratory 
questionnaire  = 
Average change 
over 6 months: air 
group = -3.6 
No 
Eves (2009) 
[46] 
Double-blind  
randomised 
controlled 
trial 
n = 38 Males: 23 
Age mean: 65.5yrs (SD 8) 
Stable  chronic obstructive 
pulmonary disease 
Baseline dyspnoea score:  
constant load exercise Borg 
mean: Air = 6.0; 2.2 
incremental load exercise Borg 
mean: Air = 5.6; 2.0 
Helium-
hyperoxia 
(60% HE: 
40% O²) 
Cylinder air Face mask  
(non-
rebreathing
) 
Modified 
Borg score 
No withdrawals 
No  Adverse 
events 
Airflow 
preferences not 
reported 
During 
exercise test 
before and 
after 6 weeks 
pulmonary 
rehabilitation 
programme, 3 
times a week 
for 30 minutes 
on cycle 
ergometer 
constant load 
exercise Borg 
mean: Air = 4.2; 
2.1 mean change 
=  -1.8 (95% CI -
3.1 to -0.2), p < 
0.05 
incremental load 
exercise Borg 
mean: Air = 5.6; 
2.1 
No change (95% 
CI -0.7 to 0.7) 
Yes 
Jolly  (2001) 
[47] 
Double-blind  
randomised 
controlled 
trial 
n = 20 Males: 19 
Age mean: 68.5yrs (SEM 2.5) 
Stable  chronic obstructive 
pulmonary disease 
Baseline dyspnoea score: 
Borg mean score 
Desat group Baseline 6minute 
walk test = 5.82 (SEM 0.46) 
Non-desat group Baseline 
6minute walk test = 4.22 (SEM 
0.46) 
Oxygen Cylinder air 3l/minute 
via nasal 
cannula 
Modified 
Borg score 
No withdrawals 
Adverse events 
and airflow 
preferences not 
reported 
Before and 
after 3 x 6 
MWTs with at 
least 
45minutes 
washout 
between walks 
Borg mean score:  
Desat group  
Air 6minute walk 
test = 5.82 (SEM 
0.42)  
No change 
Non-desat group  
Air 6minute walk 
test = 4.44 (SEM 
0.73) 
No change 
No 
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Marciniuk 
(2007) [48] 
Double-blind 
crossover  
randomised 
controlled 
trial 
n = 16 Males: 7 
Age mean: 67 (SD 8) 
Moderate to severe  chronic 
obstructive pulmonary disease 
Baseline dyspnoea score: 
Borg mean score Baseline 
6minute walk test = 5; 2 
100% 
Oxygen or 
Helium-
hyperoxia 
(70% HE: 
30% O²) 
Cylinder air 15l/minute 
via face 
mask 
8l/minute 
via nasal 
cannula 
Modified 
Borg score 
No withdrawals 
Adverse events 
and airflow 
preferences not 
reported 
Before and 
after each 6 
MWTs on visit 
1,2 and 3 with 
60 minutes 
washout 
between walks 
Borg mean score  
After 6MWT Air = 
3.5 
mean Borg score 
change = -1.5 
decrease 
Yes 
McDonald 
(1995) [49] 
Double-blind 
crossover  
randomised 
controlled 
trial 
n = 26 Males: 24 
Age mean: 73; 6 
Stable severe  chronic 
obstructive pulmonary disease 
Baseline dyspnoea score 
6minute walk test : Air group = 
3.8; 1.4  chronic respiratory 
questionnaire  = 14; 5 
Oxygen Cylinder air 4l/minute 
via nasal 
cannula 
Modified 
Borg score 
chronic 
respiratory 
questionnai
re 
Withdrawals = 7 
Adverse events 
and airflow 
preferences not 
reported 
After 6 and 12 
weeks of 
home cylinder 
air using 
6MWT 
exercise test 
with 20 minute 
washout 
between walks 
Borg Mean score 
Home air: 6minute 
walk test with 
cylinder air = 3.8 
(SD 1.5)  No 
change 
chronic respiratory 
questionnaire 
score Home air = 
17; 6 
3 point change 
No with 
6minute walk 
test 
Yes with  
chronic 
respiratory 
questionnaire 
Moore 
(2011) [50] 
Double-blind  
randomised 
controlled 
trial 
n = 143 Males: 99 
Age mean: 71.8yrs;  9.8  
Range: 43-78  
Stable  chronic obstructive 
pulmonary disease 
Baseline dyspnoea score: Air 
= 17.5; 4.9 
 Oxygen Cylinder air 6l/minute 
via nasal 
cannula at 
home for 
12 weeks 
with activity 
(SBOT) 
chronic 
respiratory 
questionnai
re 
Withdrawals = 4 
Adverse events 
not reported 
Airflow 
preferences 45% 
prefer no cylinder  
At 4 weeks 
and 12 weeks 
Air: 4 weeks = 
18.4; 5.8 
12 weeks = 18.4; 
5.8  
Air:  chronic 
respiratory 
questionnaire = 
Mean change at 4 
and 12 weeks  = 
0.9  
Yes 
Philip (2006) 
[51] 
Double-blind 
cross-over  
randomised 
controlled 
trial 
n = 51 Males: 31 
Age median: 65  Range: 33-
82yrs 
Non small cell lung cancer = 
22, Small cell lung cancer = 6, 
Breast = 8, Colorectal = 4 
Others = 11 
Oxygen Medical Air 4l/minute 
for 15 
minutes via 
nasal 
cannula  
Visual 
analogue 
scale (mm) 
No withdrawals 
Adverse events 
not reported 
Airflow 
preferences: 
Positive: n=15 
(29%)   
Before and 
after 15 
minutes of gas 
Visual analogue 
scale median 
After air 1st =  
-3mm change 
(range -19 to 7) 
Yes 
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Baseline dyspnoea score:  
Visual analogue scale median 
Air 1st = 52mm (range 23-92)  
Visual analogue scale median 
Air 2nd = 42mm (range 10-70) 
Visual analogue 
scale median 
After air 2nd =  
-11.5mm change 
(range -20 to 45)  
Visual analogue 
scale mean 
change = -
13.4mm 
Scorsone 
(2010) [52] 
Double-blind  
randomised 
controlled 
trial 
n = 30 Males: 23 
Age mean: 67.3yrs (SD 8.3) 
Moderate to severe  chronic 
obstructive pulmonary disease 
Baseline dyspnoea score: 
Before training incremental 
load exercise Borg: Air = 7; 3 
Before training constant load 
exercise Borg: Air = 8; 3 
40% Oxygen 
or Helium -
hyperoxia  
(60% HE: 
40% O²) 
Humidified 
room air 
Mouthpiec
e from a 
Douglas 
bag 
Modified 
Borg score 
No withdrawals  
Adverse events 
and airflow 
preferences not 
reported 
During 
exercise 
before and 
after a 2 
months 
pulmonary 
rehabilitation 
programme, 3 
times a week 
for 20 minutes 
on cycle 
ergometer 
After training 
incremental load 
exercise Borg: Air 
= 4; 2 
After training 
constant load 
exercise Borg = 5; 
3 
Borg change = -3 
point decrease 
both exercise 
tests 
Yes 
Wadell 
(2001) [53] 
Single-blind 
crossover  
randomised 
controlled 
trial 
n = 20 Males: 10 
Age mean: 67yrs Range: 52-
73 
Stable  chronic obstructive 
pulmonary disease 
Baseline dyspnoea median 
score:  
Test A (Air) At rest; Pre-
training Borg: Air group = 1.5 
(0-3)  
Test A (Air) After 6minute walk 
test, Pre-training Borg: Air 
group = 6.5 (4-9) 
Oxygen Air 5l/minute 
via nasal 
cannula 
Modified 
Borg score 
Withdrawals =2  
Adverse events 
and patient 
preferences not 
reported 
During 
exercise using 
2 x 6minute 
walk test 
(air/O² or 
O²/air) with 
1hour washout 
before and 
after a 2 
months 
pulmonary 
rehabilitation 
programme, 3 
times a week 
for 30 minutes 
on a treadmill 
Test A (Air) At 
rest; Post-training 
Borg: Air group = 
1 (0-3) 
Test A (Air) After 
6minute walk test 
, Post-training 
Borg: Air group = 
6 (1-7) 
Borg change =  
-0.5 point at rest 
and after exercise 
test 
Yes 
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Risk of Bias 
The quality appraisal is summarised in Online Supplementary Table 2 and described below. 
Allocation: all of the studies, apart from one, a cohort design (14), were described as 
randomised controlled trials. It was possible to verify the randomisation process in eight 
studies. (13, 16, 17, 29, 32, 45, 46, 50). There was insufficient information to determine the 
risk of allocation bias in the other randomised controlled trials. (44, 47-49, 51-53) 
Blinding: two of the fan studies attempted to blind the participants (16, 17); a placebo 
wristband was used as a comparator (16) and participants were not told if the fan to face or 
fan to leg was the active intervention. (17) There was no blinding in two studies, a cohort and 
phase II randomised controlled trial (13, 14), and the fifth study stated single blinding that 
could not be verified from the methods described. (44) All five were judged high risk of bias 
due to incomplete blinding or limited description. Nine medical air randomised controlled 
trials were described as double blind. (29, 45-52) All were judged low risk of bias (29, 45, 46, 
48-50, 52), apart from one study that was unclear due to the lack of detail reported. (51) Two 
randomised controlled trials were single blind (32, 53); one was judged low risk of bias (32) 
and the other was regarded as unclear risk due to the inadequate description. (53) 
Incomplete outcome data: 13 studies adequately addressed withdrawals and incomplete 
outcome data; these were considered low risk of bias.(13, 14, 17, 29, 32, 46-53) Three studies 
were uncertain risk (16, 45); one due to the proportion of attrition (16) and the other two 
lacked description of how any missing data were statistically managed. (44, 45) 
Selective Outcome reporting: all of the studies reported the pre-specified outcomes and were 
judged as low risk of bias. (13, 14, 16, 17, 29, 32, 44-53) Study protocols were available for 
eight studies. (13, 14, 16, 17, 29, 46, 50, 51) 
Other issues of bias: twelve studies appeared free from other bias and were judged low risk. 
(13, 16, 17, 29, 44-46, 48, 50-53) Three studies reported insufficient information to 
adequately assess risk (32, 47, 49), and one study, a cohort design was judged high risk. (14) 
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Effect of interventions 
The airflow was delivered, i) at rest (14, 17, 32, 44, 51) ii) over days or weeks (either 
intermittently or as periods of continuous flow) whilst the participant continued with usual 
general activities (13, 16, 29, 45, 50) or iii) during specific episodes of exertion induced 
breathlessness. (46-49, 52, 53) 
 
i) At rest 
Five studies demonstrated improvement with airflow delivery at rest.  
Results from 5 minutes fan use to the face in three studies were visual analogue scale 
breathlessness intensity difference from baseline mean -7mm (CI -11.5 to -2.5) (17), and 
mean -12mm (CI -19.3 to -4.4) (14), and for the numerical rating scale mean change -1.53 (-
9.6 to -6.5).(44)  
Cylinder medical air delivery for 15 minutes demonstrated improvement visual analogue 
scale breathlessness intensity mean -11mm (CI -17.0 to -5.0) (32), and mean -13mm (CI -
20.5 to-6.3). (51) Four studies were sub-divided into two groups and included in meta-
analyses. 
Fan 
Airflow from the fan at rest improved breathlessness in a mixed population (n=111; 58% 
cancer) visual analogue scale (mm) mean difference, -11.17 (confidence intervals -16.60 to -
5.74), p=0.06. Significant heterogeneity was observed, Chi² p-value = 0.2, (I² = 64%) (See 
Figure 2).  
<<insert Figure 2 Meta-analysis of fan at rest >> 
Medical air 
Airflow delivered as cylinder medical air at rest improved breathlessness in advanced cancer 
(n=89) visual analogue scale (mm) mean difference -12.0, (confidence intervals -16.6 to -
7.4), P<0.0001. No evidence of heterogeneity was observed, Chi² P value = 0.6, (I² =0%). 
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<<insert Figure 3 Meta-analysis of cylinder air at rest >> 
 
ii) General activity 
Six studies used airflow at home with everyday general activity. A narrative description was 
used for these due to study diversity. Breathlessness points change from four cylinder air 
studies were mixed (29, 45, 49, 50), with Chronic Respiratory Questionnaire -3.6 after 6 
months (45), 3.0 after 12 weeks (49), or 0.9 at 12 weeks (50), or numerical rating scale  -0.7 
(am) and -0.5 numerical rating scale (pm) after 7 days. (29) In the two fan studies a modified 
Borg score of -0.6 (SD 2.1) was found after 2 months (16), but there was no numerical rating 
scale score change after 4 weeks of fan use with exercise advice. (13) 
iii) Exertion-induced breathlessness 
Six studies examined airflow delivery with exertion-induced breathlessness. Results for mean 
Borg breathlessness score during a walking test for three studies varied; no change during a 
6minute walk test repeated on the same day (47), or at 12 weeks (49), and improvement -1.5 
for a 6 minute walk test repeated on 3 separate visits. (48) Airflow delivered during a 
constant load exercise test after PR in three studies also demonstrated variable improvement 
in mean Borg breathlessness scores; -1.8 points (46), and -3 point (52) using a cycle 
ergometer, and -0.5 point from a treadmill test. (53) Two studies were suitable to include in a 
meta-analysis (See Figure 4). (46, 52) 
Medical air  
Airflow delivered as cylinder medical air during a constant load exercise test after PR in 
chronic obstructive pulmonary disease (n=29) significantly improved breathlessness Borg 
score mean difference -2.9, (CI -3.2 to -2.7), p<0.0001. No evidence of heterogeneity was 
observed, Chi² p-value = 0.7, (I² =0%), (Figure 4). 
 
<< insert Figure 4 Meta-analysis of cylinder medical air for exertion-induced 
breathlessness>>
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Discussion 
These exploratory data support that facial and nasal airflow delivery at rest offers relief of 
breathlessness intensity consistent with a moderate clinically important difference, (54, 55) 
and during exertion. (46, 52) All participants in the cylinder medical air delivery at rest 
studies had advanced cancer, but nearly half of those in the fan “at rest” studies had other 
conditions indicating that airflow for breathlessness at rest is of benefit irrespective of cause.   
In a recent pooled qualitative data study of facial airflow use from the fan in 133 people with 
chronic breathlessness (56), over 80% patients reported some or substantial benefit.(57) 
However, the data presented here varied with regard to relief of breathlessness intensity when 
facial or nasal airflow delivery was used with everyday general activity or with exertion 
induced breathlessness. This may reflect the use of outcome measures that do not reliably 
capture change in breathlessness intensity in the context of exertion. Studies that used a 6 
minute walk test (47-49) highlight the problem of a self-paced test that allows patients to 
control their walking speed and thus limit the maximal level of exertion–induced 
breathlessness experienced. In contrast, studies that used an externally paced test, such as the 
cycle ergometer, identified relief of breathlessness intensity. (46, 52) The relationship 
between exercise and breathlessness intensity is complex, and measuring one without taking 
the other into account may miss relevant improvement. Scores are likely to remain static after 
the introduction of an intervention as patients are able to exert themselves to the same level of 
breathlessness without noticing an increase in their exercise tolerance (58), or indeed the 
outcome may be of little value to the patient. (57)  
A previous study of recovery time after an incremental shuttle walk test in people with 
thoracic cancer (n=57) reported a rapid reduction in breathlessness intensity with a return to 
baseline time of median 4 (interquartile range 2-5) minutes. (59) The analysis of 133 patient 
interviews found that a faster recovery time was a key patient-reported benefit of airflow 
delivered from the fan, irrespective of breathlessness intensity. (57) Even though recovery 
time may only be a matter of minutes, interventions which shorten this further are clearly 
welcomed and give the patient a sense of self-control that may help prevent a breathlessness-
anxiety spiral. The ability to recover quickly and predictably from bouts of exertion is likely 
to encourage further activity and prevent the deconditioning cycle. 
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The fan therefore seems suitable as a patient-delivered intervention to target the recovery 
time from exertion-induced breathlessness. Preliminary magnetoencephalography imaging 
data suggests airflow delivery during recovery from exercise may modulate central 
perception of breathlessness by modifying sensory attention. (60) Cooling of the facial skin 
innervated by the 2nd and 3rd branches of the trigeminal nerve and/or stimulation of nasal 
mucosa and upper airway ‘flow’ receptors are reported to improve breathlessness intensity 
and exercise tolerance (18, 19, 61, 62) and could “fool” the brain into thinking that the 
respiratory status is adequate. (22)  
Unpleasant respiratory sensations associated with exercise are known to adversely influence 
adherence to an exercise regime. (63) Therefore, use of airflow as part of pulmonary 
rehabilitation may help the problems of low patient attendance and poor maintenance of long 
term outcomes. (64-67) Facial airflow from fan use during a cycle ergometer test in chronic 
obstructive pulmonary disease patients resulted in significant breathlessness reduction and a 
longer total exercise time. (68) Likewise, the meta-analysis result from this systematic review 
suggest significant relief of breathlessness when airflow is delivered during exercise. These 
data highlight the potential value of using airflow delivery with pulmonary rehabilitation or 
home based exercise programmes. In addition, intervention preference and adverse event data 
support the role of the fan in this context as a portable device that is unlikely to harm and 
therefore appropriate for the majority of patients to try. 
Finally, it is likely that any positive benefits of airflow delivery from fan use with everyday 
general activity and at rest were not captured in the review data. The lack of signal from the 
results may in part reflect the complexity and the nuances of when, where and how this 
intervention is used by patients. (57) Current breathlessness management is modelled on a 
complex intervention, of which the fan is identified as a valuable therapeutic component 
alongside other interventions and strategies that are tailored to the patient’s breathlessness 
needs. (11, 69)  
Limitation of methods 
Data were analysed as cohort “before and after” design, and no adjustments were made to 
control for confounding bias. The pre-post comparison increases the potential risk of bias and 
it is possible that results may be influenced by the timing of “before and after” measures. For 
25 
 
example, studies of longer duration (up to 6 months) may not be representative of the 
immediate benefits of airflow, but rather reflect more complex use and mechanism of any 
observed benefit may be related to reconditioning, facilitated by airflow, over time. Risk of 
bias was assessed using a tool designed for randomised controlled trials therefore it is 
possible that this assessment may not capture potential sources of bias associated with the 
observational methods used in this systematic review.  
Overall, the qualitative synthesis represents findings from 929 participants the largest to date, 
however the meta-analyses pertain to a small number of participants and only provide a 
preliminary indication of the pooled effect estimate of airflow. The meta-analyses involve 
few studies therefore heterogeneity is difficult to estimate and the accuracy of the I² value is 
less certain. (70) The number of studies that fulfilled the review criteria was restricted by the 
need for baseline breathlessness measures. Some of the included studies (32, 51) did not 
report repeated measurements in a format suitable for meta-analysis necessitating statistical 
assumptions. (42) 
Implications for practice and further research 
Airflow is safe and should be used as an adjunct to treatment for breathlessness at rest in 
those who do not require oxygen-enriched air. Clinicians should consider airflow an 
important intervention to use as part of a breathlessness management programme in 
breathlessness at rest irrespective of cause. The relief of breathlessness during exertion in 
those with chronic obstructive pulmonary disease may provide a useful intervention during 
pulmonary rehabilitation where breathlessness is a reason for poor adherence. 
The fan, when taught by an appropriately trained clinician, offers patients an inexpensive and 
portable source of airflow likely to benefit exertion-induced breathlessness. Recovery time 
from exertion induced breathlessness is an important patient-reported outcome and further 
work is needed to explore the role of airflow in recovery, self-efficacy and increased daily 
activity as part of complex breathlessness intervention programmes including rehabilitation. 
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Conclusion 
These data support facial or nasal airflow for clinically meaningful relief of breathlessness at 
rest. This systematic review pulls together the growing evidence to support airflow as an 
effective self-management option for people with chronic breathlessness and identifies 
airflow as an intervention for future study.  
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